Diagnostic Evaluation of Elevated 17‑Hydroxyprogesterone for Congenital Adrenal Hyperplasia

Interpretation of Baseline 17‑OHP Levels (Endocrine Society)

The Endocrine Society defines early‑morning serum 17‑OHP thresholds: >300 nmol/L suggests classic CAH, 6–300 nmol/L suggests non‑classic CAH, and <6 nmol/L is consistent with unaffected individuals or possible NCCAH【1】【3】【2】.
Baseline values are suggestive only; the Society recommends obtaining a complete adrenocortical profile after cosyntropin stimulation to differentiate 21‑hydroxylase deficiency from other enzyme defects and to confirm diagnosis in borderline cases【1】【2】.

Premature infants physiologically have higher 17‑OHP concentrations【1】.
Immunoassay cross‑reactivity with other steroids can produce spuriously elevated results【1】【4】.
Other enzyme deficiencies (e.g., 11β‑hydroxylase deficiency, P450 oxidoreductase deficiency) also raise 17‑OHP levels【1】【2】【5】.
Heterozygous carriers may show modest post‑ACTH 17‑OHP elevations that overlap with unaffected subjects【1】【3】.

Post‑stimulation thresholds (Endocrine Society): >300 nmol/L indicates classic CAH, 31–300 nmol/L indicates likely NCCAH, and <50 nmol/L suggests unaffected status or heterozygosity【3】.
The traditional NCCAH cutoff of >1000 ng/dL (33 nmol/L) after stimulation has been questioned; newer LC‑MS/MS data propose lower, more accurate thresholds【7】.

LC‑MS/MS provides superior specificity; replacing immunoassay with LC‑MS/MS in Minnesota newborn screening increased the positive predictive value for CAH from 0.8 % to 7.6 %【4】.

Genotyping is advised when:
Genetic analysis cannot distinguish salt‑wasting from simple‑virilizing forms; this distinction relies on clinical assessment of electrolytes and plasma renin activity【1】【3】.

Prior to confirming CAH, clinicians should exclude 11β‑hydroxylase deficiency and P450 oxidoreductase deficiency, which also elevate 17‑OHP【1】【2】【5】.
A comprehensive steroid panel—including 21‑deoxycortisol, androstenedione, testosterone, deoxycorticosterone, and 11‑deoxycortisol—helps differentiate these conditions【1】【2】.

Step 1: Measure early‑morning baseline serum 17‑OHP in symptomatic patients (or during the follicular phase in women)【1】【2】【9】【7】.
Step 2: If baseline 17‑OHP falls in the intermediate range (6–300 nmol/L), perform a cosyntropin stimulation test【1】【2】.
Step 3: Obtain a complete adrenocortical profile after stimulation to identify the specific enzyme defect【1】【2】.
Step 4: Use LC‑MS/MS methodology whenever available rather than immunoassay for greater accuracy【4】.
Step 5: Reserve genetic testing for cases with equivocal hormonal results【1】【2】.
Step 6: Evaluate plasma renin activity and aldosterone to differentiate salt‑wasting from simple‑virilizing forms in confirmed CAH【1】【3】【6】.